Cannabis Stocks Falter as FDA Shares Conflicting Views on CBD After Regulatory Hearing
The fate of recent wellness rockstar, CBD—a cannabis derivative—remains unknown as the FDA debates regulation amidst growing public demand.
MORE STORIES LIKE THIS
New Jersey Supreme Court Limits Standing Under Franchise Practices Act
Health Care Hiring Slowdown Highlights In-Home Care Franchise Opportunities
Entrepreneur: This 18-Year-Old Saves Babysitting Money for College — Then Decided to Buy a Business Instead
NASAA’s Noncompete Push Puts Franchise Growth on Uncertain Ground
Featured Franchise News
Featured Brand News
/story1/2710152/ac08af5307423338edf3f61ad81ca9518948.jpg)

/story1/2729967/ccf1583647f6b1fcc43265bd125775e38622.jpg)
/story1/2730216/d82bcf367fc75f00847b708233da4e505588.jpg)
/story1/2730596/1761265520_2730596.png)
/story1/2730508/94de9d1bb08dc2079c7d87840226c0b0539.jpg)
/story1/2730547/1761081303_2730547.png)
/story1/2730489/1760471451_2730489.png)
/story1/2730615/1761335147_2730615.png)
/story1/2730613/1761333698_2730613.png)
/story1/2730603/1761325005_2730603.png)
/story1/2730600/1761317068_2730600.png)